In a clinical study on patients of first-relapse GBM, co-administration of the FASN inhibitor TVB-2640 and bevacizumab significantly improved the progression-free survival at 6 months compared with bevacizumab treatment alone [70]. This evidence concerns the gene FASN and glioblastoma.